Giovanni Caforio, MD

Chairman and CEO, Bristol-Myers Squibb

Giovanni Caforio, MD, is Chief Executive Officer of Bristol-Myers Squibb (BMS) and Chairman of the Board of Directors. He leads a company focused on discovering, developing, and delivering transformational medicines. These include a portfolio of immunotherapies that are fundamentally changing the way cancer is treated. Under his leadership, BMS has advanced its vanguard position in oncology, immunoscience and cardiovascular disease, and is developing a range of therapies for fibrotic diseases.

Giovanni was appointed as CEO in 2015 and elected as Chairman of the Board of Directors in 2017. His leadership has been marked by a strengthened patient-focused culture, emphasizing the power of innovation, speed, accountability, and passion. He has also led the company's drive to expand its global reach and promote a culture that is diverse and inclusive. Giovanni is an active champion for biomedical innovation and greater patient access to novel therapies. Reflecting his advocacy, in 2018 he was named as Treasurer of the Board of Directors for the Pharmaceutical Research and Manufacturers of America, known as PhRMA.

Prior to becoming CEO, Giovanni served as Chief Operating Officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by appointment as the company's Chief Commercial Officer.

Born and educated in Italy, Giovanni received his medical doctorate from the University of Rome. He started his career with Abbott Laboratories before joining Bristol-Myers Squibb in 2000 as Vice President and General Manager, Italy, in the Worldwide Medicines Group. Giovanni advanced through a series of regional European management positions and, in 2004, became Senior Vice President, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. as Senior Vice President, U.S. Oncology. He was named Senior Vice President, Global Commercialization, Oncology and Immunology in 2010, then became President of the company's U.S. organization in 2011.

Founded in 1887 and headquartered in Princeton, N.J., Bristol-Myers Squibb is a global enterprise whose 24,000 employees are devoted to the mission of discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases.

George D. Demetri, MD, FACP, FASCO

Senior Vice President for Experimental Therapeutics
Director, Center for Sarcoma and Bone Oncology
Quick Family Chair of Medical Oncology
Professor of Medicine & Co-Director of the Ludwig Center, Harvard Medical School
Associate Director for Clinical Sciences, Dana-Farber/Harvard Cancer Center

George D. Demetri, MD, FACP, FASCO has dedicated his career to translational and clinical research aimed at developing practical therapies from scientific mechanisms to treat life-threatening sarcomas and other cancers.

He was a pioneer in the development of imatinib (Gleevec) in gastrointestinal stromal tumors (GIST), a molecularly defined subset of sarcomas, as one of the first examples of targeted cancer therapy for a treatment-resistant solid tumor. Research from his collaborative efforts has resulted in FDA and worldwide regulatory approval of several other "smart drugs" for cancer, including sunitinib (Sutent) and regorafenib (Stivarga) for GIST, as well as pazopanib (Votrient), trabectedin (Yondelis), and eribulin (Halaven) for other sarcomas. In a related context, Dr. Demetri served on the Scientific Advisory Board for Plexxikon and was a member of the team which developed the BRAF inhibitor vemurafenib (Zelboraf) as the first mutation-targeted therapy for a molecularly defined subset of melanomas. At Dana-Farber and Harvard, Dr. Demetri is the Co-Director (along with Joan Brugge, PhD) of the Ludwig Center at Harvard, leading a collaboration of more than 30 investigative teams across Harvard-affiliated institutions to understand and overcome therapy resistance in cancers. He also directs the multidisciplinary Sarcoma and GIST Center at Dana-Farber Cancer Institute, focused on developing personalized cancer therapeutics for these mesenchymal malignancies.

Outside of the laboratory, Dr. Demetri has been instrumental in raising awareness of issues relating to the discovery and development of novel anticancer therapies, serving as a member of the clinical trials working group of the Biden-led National Cancer Moonshot Initiative, and he is the Chair of the Science Policy and Government Affairs Committee of the American Association for Cancer Research (AACR). He is Co-Chair of the Medical Advisory Board of the Sarcoma Foundation of America. Dr. Demetri also developed and teaches an innovative Freshman Seminar at Harvard College to introduce undergraduates to the social, ethical, scientific, and humanistic aspects of cancer. Dr. Demetri received his undergraduate degree in Biochemistry from Harvard College and medical degree from Stanford University School of Medicine, after which he completed his internal medicine residency and chief residency at the University of Washington Hospitals in Seattle, followed by a fellowship in Medical Oncology at Dana-Farber Cancer Institute and Harvard Medical School, where he has served as an Attending Physician since 1989.

Katherine A. Janeway, MD, MMSc

Director of Clinical Genomics
Senior Physician and Director, Solid Tumor Service, Pediatric Oncology,
Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Katherine A. Janeway, MD, MMSc, is the Director of Clinical Genomics at Dana-Farber Cancer institute as well as a Senior Attending Physician in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute and Boston Children's Hospital and an Associate Professor of Pediatrics at Harvard Medical School. Her primary areas of research focus are understanding the application of cancer genomics to the pediatric oncology clinic, and identifying central oncogenic mechanisms, novel drug targets, and new therapeutics for pediatric sarcomas —specifically gastrointestinal stromal tumor (GIST) and osteosarcoma—diseases in pediatric oncology particularly in need of scientific and clinical advances.

Dr. Janeway is the Director of the Solid Tumor Center Program for Dana Farber-Boston/Children's Cancer and Blood Disorders Center, a program that is responsible for programmatic initiatives that allow us to offer the best standard and clinical trial options to patients with solid tumors. As Vice Chair of the Children's Oncology Group Bone Tumor Committee, she is involved in setting the clinical research agenda, and guiding protocol development for collaborative studies in the childhood bone tumors Ewing sarcoma and osteosarcoma. She sits on national and local committees charged with bringing the power of genomic characterization to patient care. She leads the GAIN Consortium, a clinical sequencing consortium running a cohort study in pediatric solid tumors, and is the Co-Chair of the Target and Agent Prioritization Committee for the National Cancer Institute Pediatric MATCH study. She is the Chair Elect of the American Society of Clinical Oncology Cancer Research Committee and is on the TAPUR Study Steering Committee.

Dr. Janeway received her Doctor of Medicine from Harvard Medical School in 2000 and a Master of Medical Science from Harvard Medical School in 2008. She completed her residency in Pediatrics at Boston Children's Hospital, where she later served as Chief Resident. Dr. Janeway then completed her fellowship in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute/Boston Children's Hospital, where she joined the staff in 2007.

John M. Maraganore, PhD

CEO, Alnylam Pharmaceuticals

John M. Maraganore, PhD, has served as a member of Alnylam's Pharmaceuticals' Board of Directors since November 2011. Since 2002, Dr. Maraganore has served as the Chief Executive Officer and as a Director of Alnylam Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company. From 2002 to 2007, Dr. Maraganore served as President of Alnylam. From 2000 to 2002, Dr. Maraganore served as Senior Vice President, Strategic Product Development with Millennium Pharmaceuticals, Inc., a biopharmaceutical company (now Takeda Oncology). Before Millennium, he served as Director of molecular biology and Director of market and business development at Biogen Inc. (formerly known as Biogen Idec), or Biogen. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., a biotechnology company, and The Upjohn Company, a pharmaceutical manufacturing company.

Dr. Maraganore was formerly a Director of bluebird bio, Inc., a publicly-traded biopharmaceutical company. In addition, he was formerly a venture partner at Third Rock Ventures, L.P., where he participated in a limited capacity focusing on guiding strategy for Third Rock and its portfolio of companies, and was formerly chairman of the Board of Directors of Regulus Therapeutics, Inc., a publicly-traded company. He is also a member of the Immunology Advisory Council of Harvard Medical School and chair of the Biotechnology Innovation Organization. Dr. Maraganore holds a Master of Science and a Doctor of Philosophy in biochemistry and molecular biology from the University of Chicago, and a Bachelor of Arts in biological sciences also from the University of Chicago.